STAT+: At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director

At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.